Facebook
Twitter
LinkedIn
Instagram
Youtube
Back

Does Pro Medicus Limited have a strong and growing pipeline?

Team Veye | 14 Feb 2020 ASX - PME
Does Pro Medicus Limited have a strong and growing pipeline?

Pro Medicus Limited (ASX: PME)

Leading health imaging company Pro Medicus Limited [ASX: PME] on 13 February 2020 announced an interim after-tax profit of $12.1m for the six months ending 31 December 2019, 32.7% higher than for the previous corresponding period.

(Graphic Source Company Reports)

Highlights

  • Revenue $29.3m – up 15.7% 
  • Net profit after tax $12.1m – up 32.7% 
  • Underlying profit before tax $14.8m – up 45.3% 
  • Cash reserves $38.8m – up 20.2% 
  • Fully franked interim dividend 6c per share up 71.4% 
  • 2 key contracts announced during the period

 

Revenue from operations was $29.3m, a 15.7% increase on the previous corresponding period. Underlying revenue which excludes the one-off capital sale to the German Government made in the first half of FY2019 increased by 39.1% due to solid growth in all key jurisdictions: North America (43.1%) Europe (52.0%) and Australia (21.5%).

The company's cash reserves at 31 December 2019 were $38.8m, a rise of 20.2%. Pro Medicus announced an interim fully franked dividend of 6c per share. The company remains debt-free.

(Chart source: TradingView)

During the six-month period, Pro Medicus announced two key contract wins: Ohio State University - November 2019 – a $9 million five-year contract with the Ohio State University Wexler Medical Center, a large multi-disciplinary academic medical centre in Columbus, 

Ohio. Nines Inc - December 2019 – a $6 million five-year deal with Palo Alto-based Nines that will see Nines standardise on the Visage in the Cloud platform. (Data Source – Company Reports)

 

Veye’s Take

The interim result has provided a solid base for future growth. Pro Medicus surpassed last year’s revenue by over 15% taking into account the $3.0M one-off capital sale from the previous period. By excluding the one off capital sale in HY19 the underlying revenue growth figure is 39.1%. Pro Medicus was able to achieve this as a result of the significant step-up in its transaction revenue which grew by 30% compared to the previous 6 month period. The added benefit is that this revenue is recurring rather than one off so provides Pro Medicus with a good base for growth in the next half and future periods. Its cash balance grew by over 20% despite a bigger dividend, a share buy-back and increased tax payments. As per our earlier analysis the stock bounced from its lower support area and resumed uptrend and could gain momentum only above $25.50. The stock can have the potential of accelerating its move once above $26.80. The stock price of the company has given a return of more than 176% since Veye gave them the last buy recommendation at $9.56 on 21st Nov’18. We maintain a “Hold” recommendation on “Pro Medicus Ltd” at the current price of $26.42

Disclaimer

Veye Pty Ltd (ABN 58 623 120 865) authorised representative (AR No. 001261006) of Vested Equities Pty Ltd which holds an Australian Financial Services License (AFSL No. 478987). Veye is authorised to share only generic financial views through its website, reports and newsletters without taking into consideration your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure the accuracy of the content and that the information is gathered and processed from reliable resources, it is recommended you seek professional advice from your financial advisor or stockbroker before acting on any of our recommendations. Veye Pty Ltd advises it’s users to pursue investing as a long-term goal. Stocks are subject to real time changes therefore all the information we share represents our views at the date of publishing and we request our readers not to interpret our reports as direct recommendations. Past performance is no indication of potential future performance. The securities and financial products we study and share information on in Veye Reports may have a product disclosure statement or other offer document associated with them. You should obtain a copy of these documents before making any decision about acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Veye Pty Ltd confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report (as mentioned on the website www.veye.com.au).